Abstract:Funding Acknowledgements None. Background Senescent endothelial cells (EC) are key players in the pathophysiology of cardiovascular diseases and characterized by a reduced angiogenic and regenerative potential. Therefore, reversing EC senescence represents a promising therapeutic strategy to restore vascular integrity and increase health and lifespan. Purpose Here, we show a reversal of EC senescence following the application of a pharmacological, non-genetic, partial reprogramming strategy to induce a timely restricted induction of the Yamanaka-factors Oct3/4, Sox2, Klf4 and c-Myc (OSKM). Methods Methods to characterize the effects of pharmacological reprogramming included the quantification of gene expression as well as functional analysis of EC in vitro. In addition, the regenerative capacity of EC was evaluated in a hind-limb ischemia model in vivo in young and old C57BL/6 mice. Results The application of a pharmacological reprogramming cocktail led to a strong but timely restricted activation of the Yamanaka-factors Oct3/4, Sox2, Klf4 and c-Myc in replicative senescent ECs. This activation occurred on both mRNA and protein levels (p<0.0001), concurrently significantly reducing markers of cellular aging as p16ink4a, p14arf, TNFα, IL-1b, IL-6 and CD44 (p<0.01 respectively p<0.0001), while enhancing their cellular function. Pharmacological reprogramming notably augmented the migratory (p<0.001) and proliferative capacities (p<0.01) of the replicate senescence EC and positively influenced their angiogenic functions such as sprouting (p<0.0001) and tube formation (p<0.01). Telomere length was stabilized (p<0.05) and production of reactive oxygen species decreased (p 0.05). Over prolonged periods, the treated ECs maintained consistently low expression of aging markers (p16ink4a and p14arf, p<0.01) while preserving their migratory capabilities (p<0.05). In vivo, a significantly improved blood flow was observed after hind limb ischemia in 22 months old C57BL/6 mice after 7 and 14 days (p<0.001), alongside a significant increase in capillary density in the gastrocnemius muscle quantified by CD31 staining (p 0.05). Conclusion In conclusion, we demonstrate that a short induction of OSKM via a pharmacological approach holds the potential to reverse cellular senescence in EC in vitro with improved regenerative and angiogenic capacities and thus to enhance endothelial regenerative capacity in vivo. This might present a promising strategy for ischemic diseases.

Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence

Identification of Cellular Isoschaftoside-Mediated Anti-Senescence Mechanism in RAC2 and LINC00294

Autophagy inhibits the mesenchymal stem cell aging induced by D-galactose through ROS/JNK/p38 signalling

Supramolecular Senolytics via Intracellular Oligomerization of Peptides in Response to Elevated Reactive Oxygen Species Levels in Aging Cells.

Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence

Senescence Rejuvenation through Reduction in Mitochondrial Reactive Oxygen Species Generation by Polygonum cuspidatum Extract: In Vitro Evidence

Identification of a small molecule SR9009 that activates NRF2 to counteract cellular senescence

Therapy-induced senescence through the redox lens

Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling

Rosiglitazone Ameliorates Senescence-Like Phenotypes in a Cellular Photoaging Model.

Mesoporous Ternary Nanozymes with Anti‐Senescence and Anti‐Inflammation Activities for Atherosclerosis Management

Enhancing cellular regeneration through targeted pharmacological reprogramming of senescent endothelial cells

Dual inhibition of CDK4/6 and XPO1 induces senescence with acquired vulnerability to CRBN-based PROTAC drugs

The combination of nicotinamide mononucleotide and lycopene prevents cognitive impairment and attenuates oxidative damage in D-galactose induced aging models via Keap1-Nrf2 signaling

A DUAL MTOR/NAD+ ACTING GEROTHERAPY

Photoactivatable senolysis with single-cell resolution delays aging

Senolytics and Senomorphics Targeting p38MAPK/NF-κB Pathway Protect Endothelial Cells from Oxidative Stress-Mediated Premature Senescence

Senolytics and Dietary Phytochemicals: Exploring Anti-Aging Strategies and Mechanisms in Aging and Disease

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria